Reply to thread

Northera data is truly suspect at best in its current form ... No durability of effect, questionable long term safety.  Throw in generic competition, too many reps, and a clueless management team and you have a company that has failure to launch. 


This will take more than a year before any further FDA decision ... And more than likely, longer than that.  FDA will not be priority reviewing this drug whem Chelsea finally gets their act together, if they ever do.